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External beam radiotherapy is used to treat the postsurgical bed of primary tumours 
and regional lymph nodes in head and neck cancer treatment. As megavoltage 
photons have a skin sparing effect, bolus is used to provide dose build-up and deliver 
high doses to scar tissue on the skin. 
At the Radiation Oncology Department of Auckland City Hospital (ACH) IMRT and 
VMAT are used to treat these patients. This work investigates whether bolus 
material is necessary to ensure that the scars on the skin of head and neck 
radiotherapy patients receive an adequate dose of radiation.  
A retrospective planning study was performed to investigate whether clinically 
acceptable IMRT and VMAT plans could be developed to deliver full dose to the scar 
tissues without bolus. It was possible to generate excellent PTV coverage in all cases 
without bolus, but doses to the scar tissue were on average 12% lower than those 
produced in the original plans. The results of this study were verified with a phantom 
study and film dosimetry. 
Surface dose in the original plan with bolus measured with film was in good 
agreement with the dose predicted by Pinnacle3. However, there was considerable 
discrepancy in measured and predicted surface doses for the no bolus plans. 
Pinnacle3 overestimated the surface doses in no bolus plans.  
If the goal is to adequately treat the scar tissue whilst maintaining a good quality 
dose distribution within the target, this study demonstrates that bolus is a necessary 
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The uncontrolled growth of abnormal cells anywhere in the body is termed cancer. 
Radiotherapy, surgery and chemotherapy are the most common treatments for 
cancer - surgery and radiotherapy are used to treat localised tumours whilst 
chemotherapy is used to treat cancers which have spread.  More than half of all 
patients treated for cancer, at some stage, will require radiotherapy [1, 2].  
This thesis details work carried out to establish whether bolus material is necessary 
to ensure that the scars on the skin of head and neck radiotherapy patients receive a 
full dose of radiation. A planning study was performed to investigate whether full 
dose to the skin could be achieved without bolus via the usual planning process, as 
well as a range of other advanced planning techniques. The results of this study were 
verified with a phantom study and film dosimetry. 
The thesis begins with an overview of external beam radiotherapy including 
important radiation-tissue interactions which ultimately lead to cell kill in tumours in 
section 1.1.1. A brief description of a linear accelerator is given in section 1.1.2. 
Section 1.1.3 explains the skin sparing effect of high energy photon beams. Section 
1.1.4 introduces the various radiotherapy treatment techniques that may be used to 
treat head and neck cancer. Section 1.1.5 gives a brief description of external beam 
radiotherapy for head and neck cancer and section 1.2 gives an overview of the 
treatment planning system. The dosimetry equipment and materials best suited for 
measuring surface dose are discussed in section 1.3. Section 1.4 gives an overview of 
bolus. Finally, the objective of this thesis is given in section 1.5.   
1.1 External Beam Radiation Therapy  
1.1.1 Radiobiology 
 
External beam radiation therapy (EBRT) is a treatment modality which relies on the 
destruction of tumour cells by irradiating them with a beam of ionising radiation. 
When ionising radiation travels through matter, it loses energy through a variety of 
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processes (discussed in section 1.1.3) which result in the ionisation of local atoms.  
When the material is tissue, the ionisation events in a cell can damage the cell’s DNA 
by direct or indirect action. In direct action, single or double DNA strands are broken. 
This may lead to irreversible cell damage. In indirect action the ionising radiation 
interacts with other molecules or atoms in the cell producing free radicals. The 
highly reactive free radicals produce changes that cause biological damage. If the cell 
cannot repair itself correctly it will either become inactive or will undergo 
programmed cell death. More radiation damage means less likelihood of cell repair 
and thus a higher chance of cell death. The aim of EBRT is to cause maximum 
damage to the tumour while minimising damage to non-tumorous tissues 
surrounding it [3].  
1.1.2 Linear Accelerators 
In the early days of radiotherapy only superficial disease could be treated as the only 
available therapeutic beams were low energy X-rays which had a limited penetration 
depth.  The desire to treat tumours at greater depths required the use of higher 
energy beams and this led to the development of Cobalt-60 machines and 
subsequently to the development of the modern linear accelerator [4].  
Linear accelerators are machines which produce high energy photons and electron 
beams for radiation treatment. Modern linear accelerators have the ability to 
produce multiple electron and photon energies and they can deliver radiation doses 
at high dose rates. The linear accelerator uses microwave technology to accelerate 
electrons in part of accelerator called the ‘wave guide’. These accelerated electrons 
are then allowed to collide with a heavy metal target to produce a high energy 
photon beam (Fig. 1.1). The beam of high energy photons is shaped as it exits the 
machine to conform to the shape of the tumour. The shape of the photon beam is 
defined by collimator jaws and multileaf collimators (MLCs) made up of a high 
atomic number material. MLCs are made of two banks of interlocking tungsten 
leaves. MLCs have 40-120 leaves and each leaf can be moved individually to form an 
arbitrarily shaped field. The amount of radiation exiting the linear accelerator is 




Figure 1.1: Schematic diagram of linear accelerator [5]. 
In order to irradiate the tumour from a variety of angles, the gantry can be rotated 
around the patient lying on the treatment couch (Fig.1.2). During treatment delivery 
the patient position must replicate the planning computer tomography (CT) position 
to ensure that the radiation dose is delivered to the tumour. Hence, external 
markers are drawn on the patient’s skin at the time of CT scan and the patient is 
then positioned on the treatment couch by aligning the external markers with the 
orthogonal lasers in the treatment room [5, 6]. 
 
Figure 1.2: Gantry rotates around the patient to irradiate the tumour from different angles [7]. 
1.1.3 Photon interactions with matter 
When a photon beam of energy hν travels through a medium (for example, tissue), it 
loses energy to the surrounding medium. When a photon interacts with an electron 
(assumed at rest), a part or all of its energy is converted into kinetic energy of the 
electron. In the case of partial energy transfer, the photon itself is scattered with 
decreased energy hν’ (Fig. 1.3). The scattered photon may interact with electrons 
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resulting in partial or complete transfer of energy. The initial energy transferred from 
the photons to electrons is called collision KERMA (Kinetic Energy Released in the 
Medium) [8].  
 
Figure 1.3: Schematic diagram of energy transfer from a photon to the surrounding medium. 
KERMA occurs at one point in the medium (a) but absorbed dose occurs further downstream and 
over a path length (b) [8]. 
After receiving energy the electron traverses through the medium and loses its 
energy in collisions along its path (indicated by (b) in Fig. 1.3). The energy transferred 
along its path is called the absorbed dose. Along its path the electron may collide 
with a nucleus resulting in a bremsstrahlung photon hν” (‘bremsstrahlung loss’). This 
interaction is called radiative KERMA. An electron-electron collision may occur 
resulting in a delta ray. Both KERMA and absorbed dose have the same unit: 
joules/kg [8, 9]. 
As the photon fluence is greatest at the surface, the initial energy transfer from 
photon to electron (collision KERMA) is highest at the surface. On the other hand, 
absorbed dose (energy transferred by the electron along its path to the medium) is 
lowest at the surface (as electronic equilibrium has not yet been reached – see 
below) and increases with depth. It reaches a maximum value at zmax. If there was no 
photon attenuation or scattering in the medium, KERMA would be constant with 
depth. The region between the surface and zmax is called the build-up region. If the 
bremsstrahlung losses were ignored, the absorbed dose would be equal to KERMA 
beyond zmax. This would result in a region of charged particle equilibrium (CPE) 




Figure 1.4 : In the absence of attenuation and scattering, the number of electrons released per unit 
length remains constant and CPE is achieved [9] . 
However, in practice, the photons are attenuated and scattered in the medium and 
the number of secondary electrons also decreases.  So both KERMA and absorbed 
dose decrease. In this case the region beyond zmax is called transient charged particle 
equilibrium (TCPE) (Fig. 1.5) [8, 9, 10].  
 
Figure 1.5: Number of electrons released per unit length decreases due to photon attenuation and 
scattering in the medium resulting in TCPE [9]. 
Therefore the absorbed dose at the surface is smaller than the dose at zmax. This is 
called the skin sparing effect of high energy photon beams. It allows the optimal 
doses to be delivered to a deep seated tumour without causing severe skin 
reactions. The skin sparing effect increases as photon energy is increased [5].   
1.1.4 Conformal Radiation Therapy  
Before the advent of modern technology, radiation treatments were based on 
orthogonal X-ray images and dose was calculated manually. The beam arrangement 
was usually coplanar, with two to four opposing beams. [11, 12]. With the 
introduction of CT images and computerised treatment planning systems, it became 
possible to plan three-dimensional conformal radiotherapy (3DCRT). Multiple beams 
from different angles were directed to the tumour such that the high dose volume 
conformed to the shape of the target volume whilst sparing the normal tissues [13]. 
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Its limitation was that a large number of beams is required to achieve an optimal 
dose distribution for complex-shaped tumours [14]. 
1.1.4.1 Target Volumes 
It is important to define the target volume on the CT images for the purpose of 
planning the treatment. The International Commission on Radiation Units and 
Measures (ICRU) reports 50, 62, and 83 provide the foundations to define the target 
volumes. The three main volumes are the gross tumour volume (GTV) i.e. the 
tumour visible on planning images, the clinical target volume (CTV) and the planning 
target volume (PTV) (Fig. 1.6). The CTV comprises the GTV plus a margin for 
microscopic spread. The CTV must be adequately treated to cure the disease. The 
PTV incorporates the CTV plus margins to account for possible uncertainties in 
patient positioning, organ motion, and beam alignment. Dose is prescribed to the 
PTV to ensure that the CTV receives an adequate dose. As per ICRU 
recommendations, at least 95% of the prescribed dose should be delivered to the 
PTV to deliver full dose to the CTV [15, 16]. 
 
Figure 1.6: Main target volumes in radiotherapy [15]. 
1.1.4.2 Intensity Modulated Radiation Therapy  
Intensity Modulated Radiation Therapy (IMRT) is an advanced form of CRT in which 
the intensity profile of at least one beam is modulated. The beam intensities can be 
modulated using MLCs. Each beam is divided into several beamlets and each 
beamlet has a fixed intensity. This allows conformation to complex shapes, even 
those with concavities, such as that shown in Fig. 1.7. The superposition of 
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independent segmented fields delivered from different gantry angles produces the 
desired dose distribution, and limit dose to organs at risk [17]. IMRT plans are 
generated using inverse planning techniques. The inverse planning technique uses a 
mathematical optimization algorithm to generate a deliverable treatment plan that 
produces a dose distribution closest to the prescribed one [18].  
 
Figure 1.7: Intensity modulated beams. The beams superimpose to deliver high dose to the tumour 
whilst sparing the surrounding normal tissues [19]. 
The optimization criteria are commonly expressed in terms of dose objectives and 
weightings. The treatment planner sets desired goals for target volumes and the 
organs at risk (OARs). For example, the planner may set minimum and maximum 
dose values for the PTV and give these parameters high weighting to produce a 
homogenous dose in the PTV. The planner can also apply a ‘mean’ or ‘uniform’ dose 
constraint for the PTV. The planner may assign a maximum dose for an OAR with 
lower weighting. The optimization function then will try to achieve these goals. The 
minimum and maximum dose values for the PTV are generally 95% and 105% 
respectively based on recommendations in ICRU 83. The maximum dose limits for 
different OARs are different and are based on the Quantitative Analysis of Normal 
Tissue Effects in the Clinic (QUANTEC) guidelines. The optimization criterion can also 
be defined in terms of an equivalent uniform dose (EUD). EUD is defined as the 
biologically equivalent dose which, if given uniformly, will result in killing the same 
number of cells in a specific organ as the actual non-uniform dose distribution [18]. 
The planner also determines the number of beams and beam angles considering the 
shape, size, and location of the target volume and gives this as an input to the 
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planning system. This is called ‘beam angle optimization’. Based on the optimization 
criteria, the optimization algorithm then generates a fluence map for each beamlet 
in each beam (‘fluence map optimization’) and uses the leaf-sequencing algorithm to 
convert these fluence maps into a series of MLC shapes (segments). These segments 
are saved as an MLC leaf sequence file. The MLC leaf sequence file controls the 
movement of MLCs during treatment delivery [17, 20]. 
IMRT can be delivered by two methods – step-and-shoot and dynamic delivery. In 
step-and-shoot the photon beam switches off whilst the MLC leaves travel from one 
segment to another. The total dose at one point is the superposition of doses from 
each of the segments. On the other hand, in a dynamic delivery the MLC leaves 
move across the beam aperture at different speeds to ‘paint’ a continuous fluence 
map when the beam is on [17].  
Many studies have shown that IMRT can increase locoregional control and reduce 
toxicity, thus reducing side effects and improving quality of life [11].  However, the 
treatment time required to deliver an IMRT treatment is greater compared to 3D 
CRT. This has led to newer advanced techniques which can deliver complex dose 
distributions in a shorter treatment time [21].  
1.1.4.3 Volumetric Modulated Arc Therapy  
Volumetric modulated arc therapy (VMAT) is a rotational form of fixed gantry IMRT. 
In VMAT, the MLC leaves move as the gantry rotates whilst the beam is on. Three 
parameters – gantry rotation speed, beam aperture shape and dose rate are varied 
simultaneously during the treatment delivery to produce a highly conformal dose 
distribution with a reduced treatment time and fewer MUs compared with IMRT 
[21].  
In VMAT planning it is considered that the full arc (360° gantry rotation) can be 
represented by a number of control points. VMAT optimization starts with modelling 
the continuous gantry motion as the coarse sampling of static gantry positions. The 
fluence map at each gantry position is optimized and then converted into control 
points. Only two control points are selected and the rest are discarded. By 
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interpolating between the existing control points, new control points are added. 
Thus the gantry resolution is gradually increased until a desired control point density 
is reached (typically one control point at every 2°-4°). The machine constraints 
(gantry rotation speed, leaf translation speed, and maximum dose rate) are 
considered while optimizing these control points [22, 23]. Fig. 1.8 illustrates VMAT 
optimization.  
 
Figure 1.8: VMAT optimization process. The continuous gantry motion and MLC configuration is 
modelled as coarse sampling of static gantry positions.  As the optimization continues more 
samples are added to get desired sampling frequency [22]. 
VMAT is considered to have an advantage over IMRT such as a having shorter 
delivery time and fewer MUs whilst maintaining a comparable dose distribution. 
However, VMAT treatment planning is more challenging than IMRT planning as it is 
necessary to process a large amount of data. Furthermore, VMAT plans are 
computed as a finite series of stationary fields but the delivery is continuous. The 
constraints placed on the speed of MLC leaf translation between successive gantry 
angles can affect the delivery of the plan. All these factors must be considered whilst 
developing a VMAT plan and the plan must be delivered and verified on the linear 
accelerator before treatment delivery [23]. 
1.1.5 EBRT for Head and Neck cancer 
Head and neck cancer is a broad term that covers epithelial malignancies that occur 
in the paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx. Most 
commonly these are squamous cell carcinomas of the head and neck [24].  
For some sites, such as tongue cancer, surgical removal of the tumour may be 
curative.  If the tumour is non-resectable or if there is a risk that the surgery may 
give a poor cosmetic or functional outcome, radiation therapy is the main treatment 
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modality. It is also used as adjuvant therapy to treat the postsurgical bed of primary 
tumours and/or adjacent areas where the tumour may have infiltrated [1]. 
The geometry of the target volume in head and neck cancer is often complex. The 
complexity of the treatment increases due to the close proximity of many 
physiologically important OARs (for example, the optic nerve) near the target. Often 
the distance between the target volume and OARs is not greater than a few 
millimetres.  Therefore the goal of the treatment is not only to treat the tumour but 
also to maintain the functionality of the OARs. It can be difficult to deliver the 
required dose to the target volume whilst minimising dose to critical structures using 
conventional 3DCRT. Hence advanced conformal radiation therapy such as IMRT and 
VMAT are used (Fig. 1.9) [24, 25, 26].  
 
 
Figure 1.9: Comparison between a conventional 3DCRT and IMRT plan. a) In the 3DCRT plan the 
98% isodose line (red line) covers the high risk target volume (red ROI) as well as the low risk target 
volume (green ROI) and surrounding critical organs. b) In the IMRT plan the 98% isodose line 
conforms to the high dose region more tightly [26]. 
1.2 Treatment Planning System  
The computerised treatment planning system (TPS) plays a central role in EBRT. The 
TPS provides tools for the radiation oncologists, radiation therapists and medical 
physicists to generate beam shapes and dose distributions to achieve the treatment 
goals. During the commissioning process of a TPS, various radiation beam 
parameters (for example, central axis depth dose, beam profile etc.) are fed into the 
TPS to model the treatment beam. The TPS uses CT data sets to generate 3D models 
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of the patient’s anatomy and tumour targets. The radiation oncologist contours the 
target volumes and organs at risk (OARs) on the images. A virtual patient is created 
to generate a simulation of the treatment plan using the beam model and patient 
data [5]. 
The treatment plans are evaluated by analysing the dose distribution. The treatment 
plans are verified to ensure that the PTV is covered adequately and doses to OARs 
surrounding the PTV are low enough not to induce significant toxicity. The most 
commonly used tools for dose distribution analysis are isodose curves, dose 
distribution statistics and dose volume histograms (DVH). The isodose curves show 
the spatial distribution of dose superimposed on the CT images. Dose distribution 
statistics give quantitative information on the dose received by the PTV or OARs, 
such as minimum dose to the volume (Dmin), maximum dose to the volume (Dmax), 
and mean dose to the volume (Dmean).  The statistical characteristics also include 
dose-volume parameters such as Dv and VD. Dv is the absorbed dose that covers a 
specified volume (V) of the target. For example, D50% means the dose received by at 
least 50% of the volume. On the other hand, VD is the percentage of volume that 
receives the prescribed dose (D). For example, V95% is the percentage of volume 
receiving 95% of the prescribed dose. DVHs provide the summary of a 3D dose 
distribution within a structure displayed as a 1D curve. It is a useful tool to compare 
various treatment plans from different planning techniques. There are two types of 
DVH - differential DVH and cumulative DVH.  The cumulative DVH is most commonly 
used for treatment plan evaluation. A cumulative DVH shows the 
fraction/percentage of volume that receives at least a dose D. An example of a 




Figure 1.10: Cumulative DVH. The fraction of volume receiving at least a dose D is plotted against 
dose. For example, D95% (indicated by blue dot) for the skin ROI is 50 Gy. In other words, 95% of the 
skin ROI volume receives at least 50 Gy. 
All plans in this study were developed using Pinnacle3 treatment planning system 
(Phillips Medical Systems, Andover, MA). 
1.2.1 Pinnacle 3 
Treatment planning in Pinnacle3 starts with the contouring of different regions of 
interest (ROIs). In addition to PTVs and OARs, extra planning ROIs are needed to 
allow rapid dose fall off outside of the PTV as well as to avoid high doses to critical 
structures. For example, a ‘ring’ ROI of 0.3 mm is created around PTV to create a 
sharp dose gradient outside PTV [27].  




Figure 1.11: Flow chart for IMRT and VMAT treatment planning.  
The dose distribution in Pinnacle3 is calculated using the Collapsed Cone Convolution 
Superposition (CCCS) algorithm. In this algorithm, the incident energy fluence plane 
is projected through the CT patient representation and is attenuated using the mass 
attenuation coefficient to calculate the total energy released per unit mass (TERMA). 
The secondary electrons which receive TERMA travel away from the point where the 
initial energy was released. As they travel they deposit energy along their path. The 
energy deposition kernel accounts for the dose deposited at a point (r) from energy 





Figure 1.12: The dose deposition kernel. The energy deposition kernel accounts for the dose 
deposited at a point (r) from energy released at a different point (r’) [18].  
Three dimensional dose distributions are calculated by superposing the TERMA with 
the energy deposition kernel at that specific voxel. The doses from multiple beams 
are calculated separately and finally added together as per the corresponding beam 
weight [28].  
When megavoltage photons pass through the linear accelerator, they interact with 
various components in the head (such as the collimation system) resulting in the 
production of contamination electrons. These contamination electrons contribute to 
the surface dose. Electron contamination modelling in Pinnacle3 is simplified by 
assuming that the electron contamination does not depend on the source-to-surface 
distance or on other beam modifiers. It is modelled as an exponential fall off and is 
added to the overall dose. This can lead to significant discrepancies between the 
surface dose calculated by Pinnacle3 and the actual delivered surface dose [29, 30]. 
1.3 Dosimetry 
Radiation detectors play an important role in ensuring the correct delivery of the 
treatment plan. Radiation detectors are regularly used for quality assurance of the 
machine as well as the verification of the treatment plans. There are many different 
types of radiation detectors such as ionization chambers, radiochromic films, 
thermoluminescent detectors (TLD) etc [5, 31]. In this study, ionization chamber and 
radiochromic film are used for dose measurements. 
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1.3.1 Ionization chambers 
A cylindrical ionization chamber is an air filled cavity which is surrounded by a 
conductive outer wall and has a central collecting electrode. The wall and the 
collecting electrode are separated with a high quality insulator to minimize the 
leakage current when a polarizing voltage is applied to the chamber. The cylindrical 
ionization chambers have a typical volume between 0.04-1.00 cm3 (Fig 1.13 a). They 
are generally used for calibrating radiation beams as well as point dose 
measurements in plan verification. An electrometer is used to measure the 
generated signal [5].  
 
Figure 1.13: a) 0.04 cc cylindrical ionisation chamber. b) PPC40 parallel plate ionization chamber 
[32] 
Another type of ionization chamber is the parallel-plate ionization chamber (Fig. 1.13 
b). The parallel-plate ionization chamber consists of two parallel plate electrodes 
which are separated by a fixed distance (~2 mm). The entry window is a polarizing 
electrode and the back wall is a measuring or collecting electrode. The guard ring 
surrounds the collecting electrode. It is insulated from the collector but is kept at the 
same potential to minimize the charge leakage [5, 33]. In photon beam dosimetry, 
the parallel plate chamber is used to measure the surface dose and depth dose 
measurements in the build-up region as they have a thin entrance window and good 
spatial resolution in the z-direction. However, these chambers show over-response 
in the build-up region to some degree based on their internal dimensions. The main 
source of the over-response is secondary electrons scattering from the side wall of 
the chamber. Gerbi’s correction factors can be applied to correct the over- response. 
These factors are based on guard size, plate separation, and volume of the parallel 
plate chamber and are specific to each chamber design [34, 35, 36]. 
The calibration factors for ionization chambers can be obtained by either calibrating 
them at a secondary standards dosimetry laboratory (SSDL) or through cross-
calibration with another ionization chamber calibrated at SSDL using standard 
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protocols such as IAEA-TRS 398 [5]. The calibration factor is used to convert the 
chamber reading into absorbed dose. If the experimental conditions are different 
from the reference conditions at the time of calibration, corrections factors are 
applied [5]. The list of correction factors is given in Appendix A. 
When an ionization chamber is placed in a high energy photon beam, it introduces a 
displacement effect. The displacement effect is the perturbation of the measured 
signal, caused by the displacement of the surrounding medium by the detector. It 
depends upon the spatial dimensions of the detector. The preferred and most 
commonly used method for correcting this is the effective point of measurement. In 
this method, the volume averaged ionization within the ionization chamber is not 
reported to the chamber’s reference point but to a point within the air filled cavity 
[37].  For a parallel plate chamber, it is defined at the inside surface of its front 
window. This point is positioned at the desired depth of measurement (Fig. 1.14) 
[38].   
 
Figure 1.14: Effective point of measurement for a parallel plate chamber [39]. 
1.3.2 Radiochromic film 
While parallel plate chambers can be used for central axis depth dose measurements 
in the build-up region either in water or in a solid water slab phantom, their 
significant size makes it impossible to use them for measuring surface dose on a 
patient or anthropomorphic phantom. For this purpose radiochromic films are 
suitable, since they are extremely thin. [36]. 
Radiochromic films are insensitive to visible light. They contain a special radio-
sensitive dye in the form of microcrystals, which are embedded in a gelatin binder. 
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When the film is exposed to ionizing radiation the microcrystals polymerize and 
change the colour of the film to blue. The amount of polymerization and degree of 
colour change is proportional to the absorbed dose (Fig 1.15). The polymers absorb 
light and the transmission of light through the film can be measured with a suitable 
densitometer such as flatbed colour scanner [40].  
 
Figure 1.15: EBT3 film response to different dose levels (0.6, 1.1,1.6, and 2 Gy) . As the dose 
increases the film becomes darker [41]. 
To find out the radiation dose delivered to the film, the change in optical density of 
the film is measured (Fig. 1.16). The optical density (OD) is defined as  
OD =  −log10 (
I
I0
)     Eq. 1 
where I0 = initial intensity, I = transmitted intensity [40]  
 
 
Figure 1.16: I0 is the intensity of incident light and I is the intensity of light transmitted through the 
film. 
The OD measured is dependent on the wavelength of light used for analysis, the 
emission spectrum of the light source and spectral sensitivity of the light detector. 
To determine the relationship between absorbed dose and film response, a 
calibration curve is used. A range of known doses, which includes the dose of 
interest, is delivered to the film and the change in OD is measured to obtain the 
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calibration curve. The relationship between dose and OD is not linear. Hence 
different methods, such as polynomial fits, are used to describe the relationship [40] 
(Fig 1.17).   
 
Figure 1.17: A typical EBT3 film calibration curve. The relationship between dose and optical density 
is not linear [42]. 
1.3.2.1 Gafchromic  EBT3 
Gafchromic® dosimetry films are the most commonly used radiochromic films. The 
latest Gafchromic film introduced in the market is EBT3.  Like the previous EBT 
models, EBT3 contains lithium salt of pentacosa-10, 12-diynoate (LiPAD) as the active 
component [43]. It has a single 28 µm thick active layer consisting of the active 
component, maker dye, and stabilizers. The yellow marker dye is used for uniformity 
corrections. The active layer is sandwiched between two transparent 100 µm thick 
polyester substrate layers (Fig. 1.18). This eliminates the face-up/down orientation 
effect as it generates identical scans. The polyester layers are laminated with silica 
particles to induce a 5 µm gap between the scanner surface and film. As the gap is 
almost ten times the wavelength of visible light, the Newton Ring artifact in images is 




Figure 1.18: Configuration of GafChromic EBT3 film [45]. 
1.3.2.2 Advantages of EBT3 films 
All models of Gafchromic EBT films are self-developing.  They have a water-
equivalent atomic number, and are suitable for use in the clinical dose range (0.1-10 
Gy). Since they are relatively insensitive to visible light, film handling has become 
easier. They are energy- independent for a wide range of energies (25 MeV to 384 
keV) [46]. Their response to ionizing radiation is independent of dose rate, at dose 
rates from 0.08 to 80 Gy/min. They are thin and can be cut to the desired size and 
shape. They have high spatial resolution and low spectral sensitivity which makes 
them ideal for measurements in steep dose gradient.  The other advantage of 
radiochromic films over other dosimeters is that it is a 2D dosimeter. While other 
dosimeters (for example, ionization chamber) measure point doses, film can 
measure dose to the region of interest [47]. The previous Gafchromic EBT models 
(EBT and EBT2) suffered from Newton ring artefact. EBT3 films have a polyester film 
substrate with silica treatment which prevents the ring formation [43]. 
 1.3.2.3 Limitations of EBT3 films 
Radiochromic films do not give instant readouts. Even though post processing is not 
required, the response of the film must be converted into absorbed dose using the 
previously discussed calibration curve. For good reproducibility and reliable results, 
strict scanning protocols must be followed. As there is batch-to-batch variation in 
films, the calibration curve should be obtained for each batch. The active monomer 
(LiPAD) has a hair-like structure and after polymerization they tend to align with 
each other. This causes anisotropic light scattering. This means that the orientation 
of film during scanning affects the measured OD. Thus the film responses in 
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landscape and portrait orientation are different. If the films are scanned in landscape 
orientation during calibration, the films must be scanned in landscape direction for 
other measurements too. Otherwise it will introduce a significant error in 
measurement. Hence it is recommended to maintain the same orientation for all 
measurements. The films should always be placed in the central area of scanner to 
ensure that the non-uniformity of scanner does not affect the reading. The film 
continues to darken over time after irradiation. Therefore there should be a 
minimum 20-24 hours period between exposure and scanning. The film response can 
vary with temperature [40, 44] . 
1.4 Bolus 
As discussed in section 1.1.3, megavoltage photon beams have skin-sparing effect. 
Hence, to treat superficial lesions, such as scar tissues in postoperative radiotherapy 
for head and neck cancer, a bolus is used to provide adequate absorbed dose to the 
surficial lesions.  As the purpose of using bolus is to introduce additional tissue in the 
path of the beam at patient’s surface, the bolus material should be tissue-equivalent. 
Commonly used bolus materials are paraffin wax, cotton soaked with water, rubber, 
and jelly-like material [48]. At Auckland City Hospital, a jelly-like material with a 
physical density of 1.0 g/cm3 is used as bolus for head and neck cancer. Its thickness 
is 7 mm. The radiation oncologist draws the outline of area to be treated on the 
patient’s skin. A tracing of this outline is used to make the bolus. During the 
treatment, the bolus is placed on the region of interest. It is custom-made for each 
patient.  
 
1.5 Objectives  
EBRT is used as adjuvant therapy to treat the postsurgical bed of primary tumours 
and regional lymph nodes in head and neck cancer treatment. Hence bolus is used to 
provide dose build-up and deliver high doses to scar tissue on skin [1]. However, 
considerable time and resources are required to make bolus.  
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Studies have shown that the use of tangential beams, immobilization masks and 
including skin in the target volume in IMRT and VMAT plans can result in higher 
surface doses [49, 50, 51]. Chow and colleagues measured the surface dose with a 
metal oxide semiconductor field effect transistor (MOSFET) detector and found that 
for a prostate patient the surface dose in IMRT plans was 15% to 30% higher 
depending upon the number of beams [52].  Higgins et al [53]  investigated the 
difference between the surface dose in conventional radiotherapy with open fields 
and IMRT plan for a head and neck case study. Their study showed that the surface 
dose increased by 13% when IMRT technique was used. 
This study aims to find out whether IMRT and VMAT plans for post-operative head 
and neck cancer patients can be developed without bolus to achieve the same 
treatment goals as those with bolus, by comparing the 95% isodose coverage of the 
planning target volume (PTV) as well as the surface dose delivered by different 





2. Materials and Methods 
This chapter includes the data collection and analysis techniques as well as the 
materials used in this study. The patient selection method is described in section 2.1. 
The subsequent sections include the various aspects of treatment planning, including 
contouring ROIs, planning objectives and treatment planning techniques. Section 2.3 
describes the dosimetry study. It talks about the different aspects of radiochromic 
film dosimetry and the comparison between surface doses measured with film and 
parallel plate chamber measurement. The surface doses in the original plans with 
bolus and new no bolus plans were verified by delivering the treatment plans to a 
phantom and measuring the surface dose with film. The details of the surface dose 
verification are given in section 2.3.5. 
2.1 Patient Selection                  
For this retrospective study, ten patient plans were randomly selected from the list 
of patients who had received adjuvant post-operative IMRT for head and neck 
cancer at the Radiation Oncology Department of Auckland City Hospital (ACH). The 
patient plans were developed using Pinnacle3® Radiation Therapy Planning software 
(Philips Medical Systems). All patients were scanned with bolus already positioned 
on scar tissue on the skin. Bolus was used to increase the dose to post-surgical scar 
tissues.  
2.2 Treatment Planning Study 
The goal of the treatment planning study was to investigate whether it was possible 
to generate a clinically acceptable plan without bolus that would maintain a 95% 
isodose coverage of the planning target volumes (PTVs) whilst also delivering 
adequate dose to scar tissues on the skin. The clinical acceptability of the plan was 
determined by comparing the PTV coverage and organ at risk doses in the new plan 
with those in the original plan. A range of treatment planning techniques such as 
IMRT, 1 full arc VMAT, 2 full arcs VMAT and two-partial arcs VMAT were used to 
create the new ‘no bolus’ plans. These techniques are commonly used for head and 
neck treatment planning. An in-house script developed for plan assessment was 
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used to obtain the dose statistics for PTV, OARs and the skin ROI dose. Using this 
script, the DVH data of region of interest (both targets and OARs) are exported from 
Pinnacle3 and read into an in-house spreadsheet which calculates the dose statistics 
for that region (Dv or VD ).  An example of the plan assessment sheet (PAS) is given in 
Appendix B. 
2.2.1 Contouring  
The planning CT scan for each patient was prepared for the planning study by 
generating the following contours: The bolus was carefully outlined on each slice and 
then a skin region of interest (ROI) was added. The skin ROI was a 5 mm thick volume 
drawn under the bolus (Fig 2.1). The 5 mm thickness was chosen to include three 
layers of the skin (epidermis, dermis, and hypodermis) [54, 55].  
 
Figure 2.1: Regions of interest (ROIs). Two new ROIs- Bolus and Skin- were added to the original 
plan and other ROIs were edited to aid the optimisation process. 
In order to evaluate the effect of removing the bolus, it was necessary to cut the 
bolus from the external patient contour. The original plans were first copied and in 
the new copied plans the physical density of bolus was overridden, i.e. set to zero 
(density of air). A 3 mm strip of tissue closest to the patient’s surface was removed 
from PTVs and other ROIs for optimization purpose since the optimization algorithm 
needs to work very hard to achieve full dose here and this can result in hotspots in 
other parts of the plan.  
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2.2.2 Dose objectives 
The ‘no bolus’ planning study was divided into two parts- 1) PTV coverage 
optimization 2) Skin dose optimization. ICRU states that the PTV should be covered 
at least with 95% of prescribed dose in order to deliver adequate dose to the CTV 
[56]. Hence, in PTV coverage optimization, the goal was to get an optimal 95% 
isodose coverage of PTV and observe its effect on the skin dose. On the other hand, 
in ‘Skin dose optimization’, the plans were optimized to maintain full dose to the skin 
ROI and observe its effect on the rest of the plan. 
2.2.2.1. PTV coverage optimization 
In order to generate a new treatment plan without bolus, the dose objectives were 
initially set using departmental guidelines. Table 2.1 describes tried and tested 
parameters which help to give the optimiser a starting point to produce an 
acceptable treatment plan. The target dose objectives were then adjusted to 
produce a dose distribution which matched the original bolus plans as closely as 
possible. Following this, an assessment of the impact of missing bolus on skin dose 
was performed. 
Table 2.1: Optimization objective types in Pinnacle
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Objective type Description 
Max Dose sets the desired maximum dose in an ROI; when used for PTV usually set  at 
105 % of the prescribed dose; usually set with a low weight in PTVs (when 
combined with the Min Dose and Uniform Dose objective);  when used for 
OARs usually set at maximum dose limit for that organ. 
Min Dose sets the desired minimum dose in an ROI; used only in PTVs and usually set at 
95% of the PTV’s dose prescription (e.g. 57Gy for PTV60); provides an 
additional control of the PTV coverage when used together with the Uniform 
Dose objective; 
Uniform Dose sets the desired uniform dose in an ROI; must only be used in PTVs and given 
the same (or comparable) weight as that of the Min Dose; 
Max EUD and Min 
EUD 
used to control hotspots, cold spots or the mean dose in an ROI; requires a 
parameter “a” where:  
i. a < 1 is appropriate for ROIs representing targets. A smaller (or more 
negative) “a-value” can remove cold spots; used with Min EUD 
ii. a = 1 corresponds to the mean dose; used with Max EUD 
iii. a > 1 is appropriate for ROIs representing critical structures.  A larger 




2.2.2.2 Skin dose optimization  
To replicate the dose delivered in the original bolus plans, the percentage of 
prescribed dose to the skin ROI in the original plan was calculated for each patient 
using the formula  
% 𝑜𝑓 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑 𝑑𝑜𝑠𝑒 𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑑 𝑏𝑦 𝑠𝑘𝑖𝑛 =  
𝑀𝑒𝑎𝑛 𝑑𝑜𝑠𝑒 𝑡𝑜 𝑠𝑘𝑖𝑛
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑑𝑜𝑠𝑒
× 100              Eq. 2 
It was found that, on average, 97.2% of the prescribed dose was delivered to the skin 
ROI in the original plans. Hence two patients were selected for whom the skin dose 
was close to this average value. For these two patients, separate plans were 
generated in order to maintain this dose to the skin ROI so that the effect on the rest 
of the plan could be investigated. For example, if the prescribed dose was 70 Gy, 
then the dose to the skin ROI was optimised to 68 Gy.  
While optimizing the plans, the skin ROI was considered as a ‘cold spot’. Cold spots 
are volumes of tissue that receive doses less than prescribed dose [57]. At ACH, a 
combination of two dose objectives, minimum dose and minimum EUD, is used to 
remove cold spots. Hence, these objectives were used to deliver full doses to the 
skin ROI.  
2.2.3 IMRT 
The selected plans were originally developed using Pinnacle3 version 9.2. However, 
during the planning study, Pinnacle3 was upgraded to version 9.8. Hence the original 
bolus plans were re-computed using version 9.8. Since the beam model was 
unchanged, there was no difference in the optimization. All no bolus plans were 
generated using version 9.8.  
Step and shoot IMRT was used to generate no bolus plans with 6 MV energy and a 
dose rate of 300 MU/min. The number of beams varied according to the size and 
shape of the PTVs. The maximum number of segments was set to 80, 90 or 100 
depending upon the size and shape of PTV as well as the number of beams used. The 
minimum segment area was set to 5 cm2 and the minimum MUs per segment was 
set to 5 to ensure that the delivered treatment would match the planned treatment. 
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The final dose was calculated using the ‘Collapsed Cone Convolution’ (CCC) dose 
engine and a 0.250 cm dose grid. 
2.2.4 VMAT 
All VMAT plans were developed using Pinnacle3 version 9.8. The gantry start and 
gantry stop angles were set as shown in Table 2.2 depending on the number of arcs 
used in the plan. The collimators were rotated to reduce the tongue and grove effect 
as well as dose to interleaf leakage. The gantry spacing was 4° and the maximum 
delivery time was set to 90 sec. The dose rate was 600 MU/min.  
Table 2.2: Gantry and collimator settings for VMAT plans 




1 Full Arc 179 181 Counter-clock 
wise (CCW) 
10 
2 Full Arcs  
     Arc1 179 181 CCW 10 
     Arc2 181 179 Clockwise 350 
 
The two-partial arc VMAT plans had one partial counter clockwise arc and one partial 
clockwise arc. The gantry start and stop angle were decided according to the position 
and shape of the PTV. The collimator angles for counter clockwise and clockwise arcs 
were 10° and 350° respectively.  
2.3 Film Dosimetry 
Film dosimetry was performed to verify whether the measured surface dose was in 
good agreement with the planned dose.  
2.3.1 Film calibration  
GafChromic EBT3 films (International Specialty Products, Wayne, NJ, USA) were used 
for film dosimetry.  For the film calibration, twelve 5cm x 5cm pieces were cut from 
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lot #04141401. One film was left unexposed (0 cGy) and the remaining were 
irradiated with doses ranging from 10 cGy  to 600 cGy using a 6 MV photon beam 
from a Varian Clinac IX/ Triology linear accelerator (Varian Medical Systems, Palo 
Alto, CA) . Each piece was placed centrally in a 30cm × 30cm × 11 cm stack of Solid 
Water® (Gammex RMI, Middleton, WI, USA) at a depth of 1. 5 cm with 100 cm 
source-to-axis distance (SAD) (Fig. 2.2). The field size was 10×10 cm2. 
 
Figure 2.2: Experimental setup for film calibration and uncertainty analysis.  Each 5×5 cm
2
 piece of 
EBT3 film was placed centrally in a 30cm ×30cm × 11cm stack of Solid Water phantom at a depth of 
1.5 cm with 100 cm source-to-axis distance (SAD). The field size was 10 × 10 cm
2
. 
The dose delivered to the films was calculated from the delivered M U. A 0.6 cc 
cylindrical ion chamber was placed at a depth of 5 cm in the Solid Water phantom 
with 100 cm SAD and was irradiated with 100 MU. Three readings were obtained 
and the average was calculated. The average was corrected for the effect of 
temperature and pressure to obtain the current machine output. The deviation of 
the machine output from calibration (Oc) was obtained by taking a ratio of current 
machine output and that at machine calibration. The delivered dose was calculated 
by multiplying the MU with Oc. 
2.3.2 Scanning protocol and analysis 
A flatbed scanner Epson 10000XL scanner (SEIKO EPSON Corporation, Nagana, 
Japan) and its accompanying software EPSON SCAN v3.45E was used to digitize all 
films.  The film pieces were scanned one at a time, 24±2 hours after irradiation. The 
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scanner was switched on approximately 30 minutes prior to use to allow the scanner 
to warm up. Three empty scans were performed as part of the warm up procedure 
before scanning the films. The film pieces were placed at the centre of the scanner 
to minimize the uncertainty due to non-uniformity of the scanner. The images were 
acquired in transmission mode and 48-bit colour with a resolution of 75 dpi and 
were saved in tagged image file format (TIFF). Gloves were worn at all times when 
handling the film. 
ImagJ 1.47v software was used for the film analysis [58].  From the TPS study it was 
found that the skin doses were calculated to be in the range of 150 cGy to 200 cGy. 
Hence a dose range of 0-600 cGy was used to create a calibration curve. To select 
the most sensitive colour channel for doses in this range, the images were split into 
three channels – red, green and blue. The mean pixel values from each channel were 
extracted using a region of interest (ROI) of 5 × 5 mm2 at the centre of the film. This 
ensured that the possible artefacts due to the cutting of the film at the film edge 
were avoided. The optical density was calculated using the following equation: 
𝑂𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (𝑂𝐷) = −𝑙𝑜𝑔10( 
𝑚𝑒𝑎𝑛 𝑝𝑖𝑥𝑒𝑙 𝑣𝑎𝑙𝑢𝑒
65535
)              Eq. 3 
The net optical density (netOD) values were obtained by subtracting the OD of the 
background (unexposed) film. The netOD for each channel was plotted as a function 
of dose [58]. It was found that the red channel had a higher sensitivity for dose in the 
range of interest (Fig.2.3). Hence in this work, only the red channel data was used for 




Figure 2.3: Response of red, green, and blue channels to dose below 600 cGy. 
2.3.3 Uncertainty of EBT3 film 
The sources of uncertainty in the film dosimetry include exposure to ambient light, 
post-irradiation darkening, scanner non-uniformity, orientation of film, film 
uniformity, scanner reproducibility, and inter-sheet variation. To reduce the effect of 
ambient light, the films were kept in light-tight packets. The uncertainty in scanner 
non-uniformity was minimized by scanning at the centre of the scanner. Several 
studies reported that the differences in netOD between portrait and landscape 
directions are significant (up to 4.5 % difference) [44, 59]. It was also shown that 
differences in netOD due to film face-up/ face-down orientation were less than 0.7% 
[44, 59, 43]. Hence to minimize these uncertainties, the film pieces were marked to 
ensure that they were scanned in the landscape direction with face-up. Borca et al. 
showed that the variation in netOD was less than 0.008 (dimensionless) if the films 
were scanned between 2 hours and 24 hours after irradiation [44].  Dreindl et.al 
demonstrated that the deviations in netOD after 20 hours were 0.9% for 30 cGy and 
were reduced to negligible values at higher dose levels (≥ 200 cGy) [59]. Hence to 
reduce the uncertainty due to post-darkening, the films were digitized after 24±2 
hours. 
Uncertainty in the film uniformity was quantified by measuring the optical density of 
























was cut into ten pieces, with dimensions 5 × 5 cm2 and irradiated with 200 cGy in 
Solid Water phantom (30 × 30 × 15 cm3) at a depth of 1.5 cm with 100 cm SAD in 10 
× 10 cm2 field size. The inter-sheet variation was analyzed by measuring the OD of 
three film pieces taken from three different sheets and exposed to the same dose in 
the aforementioned experimental setup (Fig. 2.2). The single film scanner reading 
reproducibility was quantified by scanning the same piece of film ten times at the 
centre of scanner [60].  
2.3.4 Surface dose measurement with parallel plate chamber and 
Gafchromic film EBT3 
Extrapolation chambers give the most accurate surface dose. However, as they are 
not available in every centre, parallel plate ionization chambers are commonly used 
[36, 34]. As extrapolation chambers are not available at ACH, surface dose measured 
with parallel plate chamber is considered as the gold standard for the purpose of this 
study. Film is a practical solution for measuring surface dose on a phantom. 
However, it carries significant uncertainties as described in section 1.3.2.3. And a 
strict protocol has to follow to minimize the uncertainties. Therefore parallel plate 
chamber measurements were made to verify the results obtained by film.  
2.3.4.1 Parallel plate chamber measurement 
All dose measurements were performed for a 6 MV beam with 100 cm source-to-
surface distance (SSD), 10X10 cm2 field size and at different depths using a 30 x 30 x 
11 cm3 Solid Water phantom (Gammex RMI®, Middleton, USA). A parallel plate 
ionization chamber (PPC40, Scanditronix Wellhöfer, Germany) with a Unidose 
electrometer (PTW FREIBURG, Freiburg, Germany) was used to record the dose. The 
plate separation and sidewall-to-collector distance (guard ring width) of the parallel 
plate chamber were 2 mm and 3.8 mm respectively (Fig.2.4). The effective point of 
measurement was defined at 1 mm below the outer surface of the chamber. To 
correct the polarity effect, the average reading was calculated as follows- 
𝑄𝑎𝑣𝑔 =  
𝑄++𝑄−
2
                 Eq. 4 
where Q+ = dose measured with positive polarity, Q- = dose measured with negative 
polarity [34, 35].  
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The average of three readings for each depth was calculated for both polarities. Qavg 
was normalised to 100% at the maximum dose depth. 
 
Figure 2.4: Schematic diagram of parallel plate chamber. 1: the polarizing electrode. 2: the 
measuring electrode. 3: the guard ring. a: the height (electrode separation) of the air cavity. D: the 
diameter of the polarizing electrode. M: the diameter of the collecting electrode. G: the width of 
the guard ring [61]. 
The measured percent depth dose was corrected for the chamber characteristic as 
follows- 
P’(d,E) = P(d,E) – ξ(0,E)le-α(d/dmax)                     Eq. 5 
ξ(0,E) = energy dependent chamber factor = [-1.666 + (1.982IR)][C-15.8] 
where IR = the ratio of ionization at the depth of 20 and 10 cm measured at a 
constant source-to-detector distance and 10X10 cm2 field size (0.667 for the 6 MV 
beam) 
P’ (d, E) = corrected percent depth dose 
P (d, E) = relative depth ionization 
C= sidewall-collector distance (3.8 mm for PPC40 chamber) 
L = plate separation (2 mm for PPC40 chamber) 
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E = energy 
α= the constant of proportionality equal to the fractional change in the over 
response in percent, of the chamber per unit change in d/dmax = 5.5 
d = depth of the effective point of measurement below the phantom surface 
ξ(0,E)le-α(d/dmax) = calculated correction factors  
-1.666, 1.982 and 15.8 = constants from graph of percent of maximum ionization per 
millimetre of plate separation at the phantom surface plotted as a function of guard 
width or collector edge- sidewall distance [34, 35]. 
2.3.4.2 Film measurements 
For the surface dose measurement, one piece of film ( 5 x 5 cm2) was placed on the 
surface of the Solid Water phantom and 200 cGy was delivered using a 6 MV photon 
beam at 100 source-to-surface distance (SSD) in a 10×10 cm2 field. Another film 
piece with the same dimensions was kept at 1.5 cm depth and was irradiated with 
200 cGy of 6 MV photon beam with the same SSD and field size.  
2.3.5 Evaluation of surface doses in the original plan with bolus and 
new no bolus plans 
In this investigation the surface doses delivered in the original plan with bolus and 
one ‘no bolus’ plan from ‘PTV coverage optimization’ study for two patients were 
verified using film dosimetry. The selected ‘no bolus’ plans had better PTV coverage 
and skin ROI dose than other ‘no bolus’ plans in that study. Both plans were ‘2 arcs 
VMAT’ plans.   
2.3.5.1 Phantom 
The Multiplug cavity accessory of ArcCheck phantom (Sun Nuclear Corporation) was 
used as a phantom as it is cylindrical in shape and simulates the head and neck 
geometry. Its physical density is 1.045 g/cm3. It has a bezel made of clear acrylic with 
angle markers from 0° to 360°. A 0.04 cc cylindrical ionization chamber can be 
inserted into the Multiplug cavity to measure the point dose at a particular location 
[62, 63].   
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Using the angle markers on the bezel points were marked at 10° intervals on the 
surface of the phantom at a distance of 15 cm from the bezel in the superior/inferior 
direction as shown in Fig.2.5a. Radio-opaque ball bearings (BB) were placed on these 
points to help with localization and the phantom was scanned using departmental 
protocol for head and neck CT scanning. The phantom CT images were then 
imported into Pinnacle3 and a reference point ‘CT Ref’ was placed on the CT zero 
slice. Its axes intersected the BBs at 0˚, 90˚, and 270˚. An ‘Isocentre_Phantom’ point 
was created at the same position. An external contour and BB contours were 
generated. The density of BBs was overridden to 0 (density of air) since they would 
not be present for the film measurements. The physical density of the phantom was 
set to 1.045 g/cm3 [62].  
 
Figure 2.5: a) ArcCheck Multiplug insert. Ball bearings were placed at 10˚ intervals along a line at 15 
cm distance from the bezel. The ball bearings at angles 0˚, 90˚ and 270˚ (not seen in figure) were 
used for phantom setup on treatment couch. b) Detector holder for 0.04 cc chamber. The position 
of detector can be changed. 
2.3.5.2 Transferring patient plans to the phantom 
QA plans were created by transferring the patient plans to the phantom CT image 
dataset using departmental VMAT QA protocol. The treatment beams were attached 
to a new point ‘Shift Iso’ so that the plan could more closely resemble the patient 
plan.  The location of ‘Shift Iso’ was adjusted such that the bolus contour was on the 
external of the phantom and the skin contour was adjacent to the bolus contour as 
shown in Fig. 2.6. It was ensured that the bolus contour was on the external contour 
on all slices. Wherever required, the position of both bolus and skin contours were 




Figure 2.6 : The position of ‘Shift Iso’ was adjusted such that the bolus contour was on the external 
contour of the phantom. 
The new isocentre was named as ‘Shift Iso’. The distance between the centre of the 
phantom (‘Isocentre_Phantom) and ‘Shift Iso’ in all three directions (anterior-
posterior, lateral, and superior-inferior) was calculated from the co-ordinates of the 
two points. Then the couch shifts required to bring the ‘Shift Iso’ point at the 
radiation isocentre at the time of plan delivery were calculated.  Table 2.3 illustrates 
the couch shifts required for one plan. 
Table 2.3 : Calculation of couch shifts required to bring ‘Shift Iso’ at the linac isocentre. In this 
example the couch was moved towards phantom’s right by 1.7 cm (lateral shift) and down by 2.3 
cm (ant-post shift). There was no movement in sup-inf direction. 
  Lateral (cm) Ant-post (cm) Sup-inf (cm) 
Isocentre_Phantom -0.79 -2.38 0 
Shift Iso 0.86 -0.04 0 
Couch Shifts -1.7 -2.3 0 
 
It was ensured that the density of ‘Bolus’ was 1 and 0 in the original plan with bolus 
and ‘no-bolus’ plans respectively. The dose was re-computed. A dose reference point 
(‘Dose Ref’) was to be measured at delivery for the following reasons. A point dose 
measurement by a cylindrical ion chamber in a high dose, low dose gradient region is 
often used for patient plan verification as it givens a consistent and reproducible 
measurement. Therefore the aim was to verify surface dose measurement with film 
with a point dose measurement close to the center of the PTV (Fig. 2.7). The dose at 
‘Dose Ref’ point was noted from the ‘Point of Interest Dose Table’ within the TPS. A 
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dose line profile tool was used to obtain the surface dose on each slice containing 
the ‘Bolus’ and ‘Skin’ contours and an average was calculated to get the planned 
surface dose.  
 
Figure 2.7: ‘Dose Ref’ point (red circle) was placed in a high dose, low dose gradient region to 
measure point dose for verification of plan delivery accuracy. 
2.3.5.3 Location and dimensions of bolus and/or film 
The location of the bolus and/or film on the phantom was determined from the BBs. 
For example, in Fig. 2.6 the ‘Bolus’ contour is on the fifth BB on the left side of the 
phantom (right side of observer). This corresponds to a 50˚ angle. Hence during 
treatment delivery the bolus and/or film was placed near the 50˚ mark. The distance 
between the start of bolus and the zero slice (the slice containing the 
‘Isocentre_Phantom’ point) was measured to determine the position of bolus in sup-
inf direction. 
The number of slices containing bolus were counted and was multiplied by 0.2 cm 
(thickness of one slice) to obtain its length in superior-inferior direction. The width of 
the bolus in anterior-posterior direction was measured. Thus the dimensions of 
bolus used for each patient were determined and film pieces of appropriate size 
were cut for film dosimetry. To cover the film completely, boluses of bigger 
dimensions (length of film + 0.4 cm in superior-inferior direction, and width of film + 
0.5 cm in anterior-posterior direction) were prepared.  
2.3.5.4 Treatment delivery 
The phantom was set up on the treatment couch by aligning the 90° and 270° marks 
with the wall lasers and the 0° mark with the roof laser to match the position at CT. 
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The appropriate couch shifts were applied to bring the ‘Shift_Iso’ point at the 
isocentre.  A 0.04 cc cylindrical ionization chamber was inserted in the detector 
holder to measure the dose at ‘Dose Ref’ point. Radiochromic EBT3 film was placed 
on the region of interest and was secured using tape. It was ensured that the tape 
covered the film no more than 0.5 cm from the edges. Bolus was placed on the film 
during the delivery of original plans with bolus (Fig. 2.8b).  
Each plan was delivered twice and the doses were recorded with film and the ion 
chamber. The ion chamber measurements were corrected for various parameters 
and converted into the absorbed dose by applying a calibration factor. Surface doses 
were obtained from film measurements using the calibration curve.  
 
 
Figure 2.8: a) Phantom set up on the treatment couch with EBT3 film placed at area of interest. b) 




3. Results and Discussion 
This chapter is divided into two sections - treatment planning study and film 
dosimetry. The treatment planning section includes the analysis of the treatment 
plans in terms of the planning target volume (PTV) coverage and skin dose. The 
dosimetry section includes results of the film calibration as well as an analysis of the 
uncertainties in film dosimetry. Surface dose measured with film was validated by 
the surface dose measured with a parallel plate chamber. Analysis of the surface 
dose measurements using a parallel plate chamber and film is given, and finally the 
surface dose measured by film on the phantom for patient plans are evaluated.  
3.1 Treatment Planning Study 
As stated in section 2.2.2, the treatment planning study was divided into two parts – 
optimising the PTV coverage and optimising the skin ROI dose.  
3.1.1 Optimising the PTV coverage  
In all patient plans, the PTV was extended up to the patient’s surface to treat the 
scar tissue (Fig. 3.1 a). The required build-up was provided by bolus. Hence, the 
optimizer could easily deliver dose near the surface without causing hotspots in 
other parts of the plan. However, as the bolus was removed in the new no bolus 
plans, a part of the PTV was shifted into the build-up region. Therefore, as 
mentioned in section 2.2.1, a 3 mm strip of tissue closest to the patient’s surface was 
removed from the PTV to prevent Pinnacle3 from driving the optimiser too hard in 
the build-up region, which can lead to over-modulated plans and poor quality dose 
distribution (Fig. 3.1 b). Hence, the PTVs in the original plan with bolus and the new 
no bolus plans were slightly different. However, as the goal of the treatment was to 
treat the PTV extended up to the patient’s surface, doses to this PTV were reported 
for all patients.   
ICRU states that the PTV should be covered with at least with 95% of prescribed dose 
in order to deliver adequate dose to the CTV [56]. Hence, in this study, plans without 
bolus were produced to achieve at least 95% isodose coverage of the PTV. 





Figure 3.1 : a) The PTV (green colourwash) in the original plan with bolus was extended up to the 
patient’s surface. Doses to this PTV were reported for all patients. b) A 3 mm strip of tissue closest 
to the patient’s surface was removed from the PTV to avoid optimization problems in the build-up 
region. The modified PTV is shown in purple colourwash. 
The PTV coverage was quantified using a parameter known as V95%, which is the 
proportion of the target volume receiving 95% of the prescription dose. For example, 
“V95% = 98%” means 98% of the PTV volume is receiving 95% of the prescribed dose. 
Based on the ICRU guidelines and discussion with the clinicians, a plan with V95% ≥ 
95% for the PTV is clinically accepted at Auckland City Hospital (ACH). To analyse the 
impact of missing bolus on the skin ROI dose, the mean dose to the skin contour in 
each plan was normalised to the prescribed dose using Eq. 2. 
3.1.1.1 Case-by-case comparison of the PTV coverage and dose to the 
skin  
The main objectives of a treatment plan is – to achieve optimal PTV coverage (V95% ≥ 
95%), to keep doses to the OARs within their tolerance limit, and to limit the 
maximum dose in the overall plan to less than 110% of the prescription dose. 
However, each patient is a unique case in terms of the extent of the tumour, the size 
and shape of the tumour and the adjacent anatomy. Hence, each patient plan is 
different and it can be difficult to make comparisons of planning parameters from 
one patient to another. In this section, the PTV coverage and dose to the skin are 
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evaluated on a case-by-case basis. For each patient, the no bolus plan, regardless of 
the technique, which best achieved the planning objectives was compared with the 
original bolus plan.  
3.1.1.1.a Patient 1 
 
Figure 3.2 : Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 1. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
The PTV coverage in the original plan with bolus and new plan without bolus was 
98.9% and 97.6 % respectively. Corresponding normalized mean skin ROI doses were 
96.33% and 88.67 %. As seen in Fig. 3.2, the PTV is a narrow strip and the bolus 
covers only a small portion of the PTV. Hence removing the bolus did not have a 
significant effect on the overall PTV coverage and it was possible to achieve clinically 
acceptable PTV coverage fairly easily.  
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However, it did have a major effect on the skin ROI dose. In the original plan with 
bolus, a large portion of the skin ROI was included in the PTV and the required build-
up was provided by bolus. Hence, as seen in dose volume histogram (DVH) of the 
original plan with bolus, 95% of the skin ROI received at least 50 Gy. In other words, 
D95%
 of the skin ROI was 50 Gy.  On the other hand, D95% of the skin ROI was only 30 
Gy in the no bolus plan. Thus the reduction in D95% was 40%.  This was due to the fact 
that in the no bolus plan, a substantial part of the skin ROI had to be excluded from 
the PTV (Fig.3.1 b) to prevent Pinnacle3 from driving the optimiser too hard in the 
build-up region, which can lead poor quality dose distributions. Hence, the dose to 
the skin dropped significantly when bolus was removed. In the simplest terms, the 
removal of bolus shifts part of the PTV into the build-up region, thus reducing dose 
to the skin ROI in that area.  
3.1.1.1.b Patient 2
 
Figure 3.3: Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 2. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 




The PTV coverage in the original plan with bolus and new plan without bolus was 
98.1% and 97.10% respectively. The corresponding normalized skin ROI doses were 
95.67% and 86.50 %. In this case, the PTV was crescent shaped and extended 
bilaterally.  The bolus was positioned centrally on the neck (Fig.3.3). The bolus did 
not cover the full extent of the PTV, and this may be part of the reason why there 
was a very small detrimental effect on the PTV coverage.  
The DVH of the original bolus plan (Fig.3.3) shows that the skin D95% was 52 Gy, 
compared with 35 Gy in the new plan without bolus, i.e. a decrease of 32.7%. Just as 
in patient 1, exclusion of the skin ROI from the PTV and the proximity of the PTV to 
the surface in the absence of bolus resulted in lower dose to the skin. 
3.1.1.1.c Patient 3 
 
Figure 3.4: Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 3. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
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The PTV coverage in the new plan without bolus was marginally better than the PTV 
coverage in the original plan with bolus (95.80% and 94.80% respectively). In this 
case, an OAR (left brachial plexus) was overlapping the PTV (Fig. 3.5). Brachial plexus 
is the network of nerves that controls the movement and sensation in the upper 
limbs.  In the original bolus plan, the PTV coverage had been compromised to limit 
the dose to the left brachial plexus. Based on the Quantitative Analysis of Normal 
Tissue Effects in the Clinic (QUANTEC) guidelines, for the prescribed dose of 48 Gy to 
the PTV, the tolerance limit for brachial plexus was 48 Gy.  In the new no bolus plan, 
both objectives (V95% for PTV > 95% and dose to brachial plexus (47.5 Gy) within 
tolerance limit) were achieved. This is most likely to be a result of the treatment 
technique (2 full arcs VMAT) used in the new no bolus plan. A VMAT plan with 
multiple arcs has more control points than single arc VMAT as well as IMRT which 
means that there is a much higher number of possible MLC positions and therefore a 
higher degree of modulation resulting in better plan quality, especially for a 
complex-shaped target volume [64, 65].  
 
Figure 3.5: Left brachial plexus (orange colourwash) overlapped the PTV (green colourwash). 
However, as with the previous cases the skins ROI dose in the new no bolus plan was 
considerably lower than that in the original plan with bolus (88.75% and 97.50% 
respectively). Skin D95% in the original plan was 42 Gy compared with a very 
significantly reduced 27 Gy in the new plan. A considerable part of the skin ROI was 
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included in the PTV in the original plan. Hence 95% of its volume received high dose. 
However, as stated in earlier cases, removal of a major portion of the skin ROI from 
the PTV and the closeness of the PTV to the surface in the absence of bolus caused 
lower doses to the skin.  
3.1.1.1.d Patient 4 
The PTV coverage in the original plan with bolus and new plan without bolus was 
98.1% and 99.40% respectively. Corresponding normalized skin ROI doses were 
96.44% and 89.33%. The PTV was on a narrow strip on the left side of the patient 
and was long (16.6 cm) in superior-inferior direction. In comparison to this, the 
length of the bolus was 3 cm and as seen in Fig. 3.6, it covered only a very small part 
of the PTV in anterior –posterior direction. The volume of PTV was 340.88 cm3 whilst 
volume of the skin ROI was 3.37 cm3 i.e. the skin ROI was very small compared to the 
PTV. This may clarify the reason why removing the bolus did not have any effect on 
the overall PTV coverage and it was possible to achieve clinically acceptable PTV 
coverage fairly easily. However, as observed in previous case studies, it did have a 
major effect on the skin ROI dose. D95% of the skin ROI in the original plan with bolus 
and the new no bolus plan was 38 Gy and 25 Gy respectively. The decrease in D95% 
(21.9 %) can be attributed to the exclusion of the skin ROI from the PTV and the 




Figure 3.6: Comparison between PTV coverage in the original IMRT plan with bolus and the new 
IMRT plan without bolus for Patient 4. The upper panels show the PTV (green colourwash), the skin 
ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. The lower panels 
show the dose volume histograms (DVHs) for both plans. 
3.1.1.1.e Patient 5 
The PTV coverage in the original plan with bolus and the new no bolus plan was 
98.2% and 97.70% respectively. Corresponding normalized skin ROI doses were 
99.83% and 94.00% respectively. The PTV was a long narrow strip on the left side of 
the patient and was much larger in length (19.6 cm) and volume (295.41 cm3) than 
the bolus (length = 7.2 cm and volume = 12.31 cm3). Hence, removing bolus may not 
have a significant effect on the PTV coverage.  
 
Figure 3.7 : A significant part of the skin ROI (red contour) was part of the PTV (purple colourwash) 
in the new non bolus plan of Patient 5. 
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The reduction in the skin ROI dose was less compared to previous case studies as a 
considerable part of the skin ROI was still included in the PTV used for optimization 
in the new no bolus plan (Fig. 3.7). D95% of the skin ROI was 55 Gy and 45 Gy in the 
original plan with bolus and the new no bolus plan respectively.  
 
 
Figure 3.8: Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 5. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
3.1.1.1.f Patient 6 
The PTV coverage in the original plan with bolus and new plan without bolus was 
99.0% and 97.10% respectively. Corresponding skin ROI doses were 100% and 
88.50%. The PTV extended bilaterally and the bolus covered only a small portion on 
the neck. Hence it was still possible to achieve clinically acceptable PTV coverage in 
absence of bolus. As observed in previous case studies, D95% of the skin ROI in this 
case, also was considerably lower in the plan without bolus (32 Gy) as compared to 
the original plan with bolus (57 Gy). As the skin ROI was completely inside the PTV in 
the original plan with bolus, it received full dose. Conversely, it received a much 
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lower dose in the plan without bolus as most of it had to be excluded from the PTV 
as explained in previous cases.  
 
Figure 3.9: Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 6. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
3.1.1.1.g Patient 7 
The PTV coverage (V95% = 96.90%) in the new no bolus plan was clinically acceptable.  
The PTV was a narrow strip on the right side of the patient’s neck. The length of the 
bolus in the superior – inferior direction (114 mm) was comparable with the length 
of the PTV in superior-inferior direction (126 mm). In other words, the bolus was 
present almost in every slice in the CT image data. Although the bolus extended the 
full length of the PTV, Fig. 3.10 shows that it was small compared to the size of the 
PTV in the anterior-posterior direction.  This may help explain why it was possible to 
achieve clinically acceptable PTV coverage even in absence of the bolus.  
47 
 
With regards to the skin, the trend noted above i.e. significant dose reduction to the 
skin ROI was also observed here. There was a 40% decrease in D95% in the new no 
bolus plan (30 Gy) compared to D95% in the original plan with bolus (50 Gy).  
 
 
Figure 3.10: Comparison between PTV coverage in the original IMRT plan with bolus and the new 1 
full arcs VMAT plan without bolus for Patient 7. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
3.1.1.1.h Patient 8 
The PTV coverage in the original plan with bolus and new plan without bolus was 
99.4% and 97.50% respectively. The length of the bolus in the superior – inferior 
direction was 16 cm whilst the length of the PTV in superior-inferior direction was 
22.6 cm. However, volume of bolus (21.5 cm3) was small compared to volume of the 
PTV (392.47 cm3). This means that although the bolus almost extended across the 
full length of the PTV, it was small compared to the PTV.  This may help explain why 
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it was possible to achieve clinically acceptable PTV coverage even in the absence of 
the bolus.  
However, the skin ROI dose was greatly reduced in the new no bolus plan. The whole 
skin ROI was in the PTV. Hence, it received full dose in the original plan with bolus 
(D95% = 42 Gy). On the other hand, D95% in the new plan without bolus was 25 Gy. 
Thus there was a 40.5% decrease in D95% in the new no bolus plan.  
 
Figure 3.11: Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 8. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
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3.1.1.1.i Patient 9 
 
Figure 3.12: The PTV (green ROI) is extended deeper into head and neck. The bolus (blue ROI) 
covers only a small portion of the PTV. 
The PTV coverage in the original plan with bolus and new plan without bolus was 
97.6 % and 97.5% respectively. The PTV was on left side of the patient and as seen in 
Fig. 3.12, it was deeper in the lateral direction. Its length was 8.8 cm in superior-
inferior direction and volume was 255.91 cm3. Conversely, the length and volume of 
the bolus was 1.8 cm and 4.35 cm3 respectively. Thus only a part of the PTV was 
covered with the bolus. This may explain why the PTV coverage was not affected in 
the new no bolus plan. 
However, the skin ROI dose was significantly lower in the new plan without bolus. 
The normalised skin ROI doses were 95.43% and 83.14% in the original plan with 
bolus and the new no bolus plan respectively. In comparison to plans without bolus 
in the other case studies, dose to the skin ROI here is the lowest. As stated in section 
2.2.1, usually a 3 mm strip of tissue closest to the patient surface is removed to avoid 
optimization problems in the build-up region. However, in this case, based on clinical 
consideration, the physician instructed the planners to remove a 5 mm strip of 
tissue. This did not cause any problem in the original plan with bolus as the skin ROI 
was still in the PTV (Fig.3.14 a). But, in the new no bolus plan, since the skin ROI was 
of 5 mm thickness, it was completely removed from the PTV (Fig.3.14 b). Therefore it 






Figure 3.13: Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 9. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
 
Figure 3.14: a) The skin ROI (red contour) was part of the PTV in the original IMRT plan with bolus. 
b) The skin ROI (red contour) was completely removed from the PTV (purple colourwash) in the 
new no bolus plan. 
3.1.1.1.j Patient 10 
The PTV coverage in the original plan with bolus and new plan without bolus was 
99.2% and 98.20% respectively. The corresponding skin ROI doses were 100% and 
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93.67 %. The PTV was a narrow strip with length 11.6 cm in superior-inferior 
direction whilst the length of bolus was 4.2 cm in superior-inferior direction. As seen 
in Fig. 3.15, only a small part of the PTV was covered with bolus in anterior-posterior 
direction. Hence, removal of the bolus may not have a significant effect on the 
overall PTV coverage. 
As seen in Fig. 3.15, the skin ROI was completely embedded inside the PTV. Hence, it 
was delivered full dose in the original plan with bolus (D95% = 59 Gy). On the other 
hand, as it was excluded from the PTV in no bolus plan, D95% was 35 Gy in the new no 
bolus plan.  
 
Figure 3.15: Comparison between PTV coverage in the original IMRT plan with bolus and the new 2 
full arcs VMAT plan without bolus for Patient 10. The upper panels show the PTV (green 
colourwash), the skin ROI (red contour) and bolus (sky blue).  The 95% isodose line is shown in blue. 
The lower panels show the dose volume histograms (DVHs) for both plans. 
A common trend was observed in all case studies. The bolus was small compared to 
the PTV in all cases. Hence, an absence of bolus may not have affected the overall 
PTV coverage significantly. However, the exclusion of the skin ROI from the PTV and 
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proximity of the PTV to the surface in the absence of bolus may have degraded dose 
to the skin ROI in the new no bolus plans.  
3.1.1.2 Overall comparison of the PTV coverage and dose to the skin 
ROI 
Fig. 3.16 shows the PTV coverage obtained for the full range of advanced 
planning/treatment techniques used in this study for an example patient.  
 
Figure 3.16: Summary of PTV coverage achieved for one patient expressed with V95%. IMRT, ‘1 full 
arc VMAT’, ‘2 full arcs VMT’ and ‘2 partial arcs VMAT’ are all no bolus plans. 
It was possible to achieve clinically acceptable coverage for all plans for this patient. 
In fact it was possible to cover 97% of the PTV with the 95% isodose in all cases. The 
PTV coverage obtained in the ‘2 full arcs VMAT’ plan was better than the rest of the 
plans including the original plan with bolus.  
Fig. 3.17 shows the comparison between the PTV coverage (V95%) in various 
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clinically acceptable PTV coverage (V95% ≥ 95%) in all no bolus plans for all patients 
was achieved. 
 
Figure 3.17: Comparison between the PTV coverage (V95%) in various trials for all case studies. As 
before, IMRT, ‘1 full arc VMAT’, ‘2 full arcs VMAT’ and ‘ 2 partial arc VMAT’ are all ‘no bolus’ plans. 
Among the no bolus plans, ‘2 arcs VMAT’ plans gave better results in seven cases 
(Table 3.1) whilst IMRT plans were better in two cases. In one case, ‘1 arc VMAT’ 

























Table 3.1: PTV coverage obtained in ‘no bolus’ treatment plans for ten patients. As indicated by the 
values in bold , ‘2 arcs VMAT’ plans had better coverage in seven cases whilst ‘1 arc VMAT’ was 
slightly better in one case. IMRT plans had greater PTV coverage in two cases.  As the PTV coverage 
in ‘2 partial arcs VMAT’ plans was lower than other no bolus VMAT plans, they were generated only 
for three patients.  
Patients  
 IMRT  
1 full  arc 
VMAT  
2 full arcs  
VMAT  
2 partial arcs  
VMAT 
1 97.90 98.40 98.90 97.60 
2 96.00 96.50 97.10   
3 93.30 94.70 95.80   
4 99.40 97.50 98.70 96.80 
5 96.90 97.50 97.70 97.20 
6 97.10 96.20 96.70   
7 96.50 96.90 96.40   
8 96.00 97.00 97.50   
9 96.60 97.00 97.50   
10 96.50 97.50 98.20   
 
To analyse the impact of missing bolus on the skin ROI dose, the mean dose to the 
skin contour in each plan was normalised to the prescribed dose using Eq. 2. Fig. 3.18 
shows the normalized skin ROI doses in treatment plans for the example patient 
given in Fig. 3.16. It is evident from the graph that the normalised skin ROI dose in 





Figure 3.18: Mean skin ROI dose normalized to the prescribed dose in various trials for one patient. 
Fig. 3.19 shows the normalized mean skin ROI doses to all patients in this study. The 
normalized mean skin ROI dose in all no bolus plans was significantly less than that in 


































Figure 3.19: Normalized mean skin ROI doses in all plans for ten patients. The normalized mean skin 
ROI doses in ‘non- bolus’ plans were significantly less than that in the original plan with bolus. 
Table 3.2 shows the mean normalized skin ROI dose for ten patients for each 
treatment planning technique. The skin ROI dose achievable without bolus was 
found to be significantly lower than that in the original plans with bolus. The average 
decrease in the skin ROI dose was 10.44%, 9.24%, and 8.48% in IMRT, ‘1 full arc 
VMAT’, ‘2 full arcs VMAT’ respectively.  









97.18±2.41% 86.74±5.82% 87.94±5.59% 88.70±5.16% 
 
Normalised skin ROI doses in plans without bolus for individual patients are given in 
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With bolus  IMRT 1 arc VMAT 2 arcs  VMAT 2 partial arcs  VMAT
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cases whilst ‘1 full arc VMAT’ gave better results in two cases . In one case, IMRT 
plan had a better outcome than other two techniques. However none of these 
techniques were able to produce a skin ROI dose that would have been clinically 
acceptable, as in the bolus plan.  
Table 3.3: Normalised skin ROI doses in treatment plans without bolus for ten patients. 
 
Normalised skin ROI dose in plans without bolus (%) 
Patients 
 IMRT  1  full arc VMAT  2 full arcs  VMAT  
1 85.00 87.17 89.00 
2 83.00 85.00 86.50 
3 85.42 87.71 88.75 
4 89.33 87.78 90.44 
5 91.33 95.00 94.00 
6 88.50 87.17 86.67 
7 81.33 85.00 83.67 
8 82.08 83.75 84.79 
9 81.43 80.86 83.14 
10 90.33 92.17 93.67 
 
At ACH, the clinically acceptable global maximum dose (i.e. a maximum point dose 
anywhere in the plan) for IMRT and VMAT plans is 110% of the prescribed dose. This 
tolerance is adapted from the ICRU recommendation for IMRT and VMAT plans [16]. 
The global maximum dose in all no bolus plans in ‘PTV coverage optimization’ study 
was less than 110% of prescribed dose. 
The results obtained in this section of treatment planning system (TPS) study showed 
that it was possible to achieve good PTV coverage without using bolus. However, the 
absence of bolus caused significant reduction in the skin ROI dose.  
3.1.2 Optimising the skin ROI dose 
In this section, the no bolus treatment plans were optimized to replicate the dose 
delivered to the skin in the original bolus plan and the overall impact on the dose 
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distribution was reported. In these plans, the skin ROI was considered as a ‘cold spot’ 
and the plans were optimized to deliver full doses to it.  
Fig. 3.20 shows that in all no bolus plans the normalised skin ROI dose was greater 
than 97%. Thus it was possible to reproduce the dose delivered to the skin in the 
original plan. However, this approach had an adverse effect on the PTV coverage. For 
patient 3, the PTV coverage in the IMRT plan was comparable with the PTV coverage 
in the original plan with bolus. However, it was degraded in both VMAT plans 
without bolus.  For patient 7, the PTV coverage in all plans without bolus was 
significantly smaller than the PTV coverage in original plan. Fig. 3.21 shows the PTV 
coverage in the original plan with bolus and a new plan without bolus for patient 3. 
Whilst the PTV in original plan with bolus gets at least 95% of the prescribed dose, a 
significant part of the PTV is underdosed in the new no bolus plan.   
 
Figure 3.20: The effect of optimizing dose to the skin ROI on normalised skin ROI dose, PTV 




Figure 3.21: Comparison between PTV coverage in the original plan with bolus and the new 1 full 
arcs VMAT plan without bolus for Patient 3. 95% isodose line (blue) conforms well to the PTV 
(green colourwash) in original plan with bolus. However, it does not conform tightly to the PTV in 
the new bolus plan without bolus. 
The skin ROI was in the build-up region of megavoltage photon beam which is a low 
dose region (as discussed in section 1.1.3). When the plan was optimized to deliver 
high doses in this region, the optimizing algorithm attempted to increase the dose by 
creating intensity peaks in fluence maps [57]. This caused hot spots in the plans 
outside the target volume. Hot spots are volumes of tissues that receive doses 
greater than the prescribed dose. If the hot spots are in normal tissues, they can 
cause severe damage. Hence hot spots outside the target volumes are undesirable 
[16]. As seen in Fig. 3.20, the global maximum doses in the new no bolus plans were 
above tolerance limit (110%). Hence, these plans would not be clinically acceptable.  
The treatment planning needs a considerable amount of time and resources. In the 
‘skin ROI dose optimization’ study, three no bolus plans were generated per patient. 
All these plans were suboptimal (inadequate PTV coverage and hotspots in normal 
tissues) and would not be clinically accepted. Hence, this method was not attempted 
for other patients. 
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3. 2 Dosimetry 
3.2.1 Film calibration and uncertainty analysis 
EBT3 films were calibrated for a dose range of 0 - 600 cGy. Mean pixel values 
obtained using the ImageJ software were converted into optical density (OD) using 
Eq. 3. The netOD values were obtained by subtracting the OD of an unexposed 
(background) film. The calibration curve was fitted with a third order polynomial (R2= 
0.99961) (Fig.3.22) [66]. 
 
Figure 3.22: Calibration curve of EBT3
 
film for 6 MV photon beam. 
The relative uncertainties in the doses measured by film are given Table 3.4. 
Table 3.4: Uncertainty determination for EBT3 film 
Source of uncertainty Relative uncertainty (%) 
Film Uniformity ±0.84 
Inter-sheet variation ±1.38 
Single film scanner reading reproducibility  ±0.48 
 
The combined relative uncertainty was calculated by a quadrature sum of the above 
uncertainties (assumed as independent) as follows: 
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝑢𝑛𝑐𝑒𝑟𝑡𝑎𝑖𝑛𝑡𝑦 =  √0.842 + 1.382 + 0.482 = 1.69%           Eq. 6 


















Calibration Curve  
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3.2.2 Surface dose measurement with a parallel plate chamber and 
EBT3 films 
Doses at a range of depths from the surface (0 mm) to 15mm were measured with a 
PPC40 parallel plate ionization chamber and were normalised to 100% at the depth 
of maximum dose (15mm). The percentage depth dose (PDD) data thus obtained is 
shown in Table 3.5. The effective point of measurement for a PPC40 is 1 mm below 
the entrance window. The depths were corrected accordingly.  
Table 3.5: Percentage depth dose in build-up region measured with a PPC40 ionization chamber 
Corrected 









Measured PDD values were corrected for over-response in the build-up region using 
Eq. 5 and were plotted against depth as shown in Fig. 3.23. A 6th degree polynomial 
(R2 =1) was fitted to the corrected data and the surface dose was obtained by 
extrapolating the curve to a depth of 0. The percentage surface dose was found to 
be 17.6%.  
Bilge et al. [35] measured surface dose with a Markus parallel-plate ionization 
chamber. They found that the surface dose for a 6 MV photon beam with a field size 
of 10 × 10 cm2 was 15.0%.  Jong and colleagues measured surface dose with a 
Markus chamber and the result for a 10 x 10 cm2 6 MV photon beam was 
15.83±0.03% [67]. In another study, the surface dose measured with an Attix 
parallel-plate ionization chamber was 18.95% [68]. Akbas et al. [36] showed that the 
surface dose measured with a Markus chamber was 16.61%. In a Monte Carlo study, 
the surface dose for 10 x 10 cm2 6 MV photon beam was 16.45% [69] .  In the 
present study, the surface dose measured with a PPC parallel-plate chamber was 




Figure 3.23: Corrected PDD. Percentage depth dose data obtained with a PPC40 chamber were 
corrected for over-response in the build-up region using Gerbi’s correction factors. 
Percentage surface dose measured with EBT3 film was found to be 20.9 ± 2.4%. This 
value was in close agreement with the surface dose measured by Akbas et al. In their 
study, percentage surface dose measured with EBT3 film was 20.4% [36].  
The results obtained in this study showed that surface dose may be overestimated 
by 3.3% with EBT3 Gafchromic film measurement with respect to the PPC40 
ionization chamber for 6 MV photons.  This is comparable with the results of the 
investigation by Bilge et al. [35]. In their study, the surface doses measured with EBT 
film were 5% higher than the parallel plate ionisation chamber measurements for a 6 
MV beam.  
The surface dose is defined as the dose deposited within an infinitesimally small 
mass of matter at the surface of the phantom/patient. However, the radiation 
detectors do not have an infinitesimally small sensitive volume. Hence, surface dose 
measurements are fundamentally difficult. For practical reasons, the dose measured 
at the effective point of measurement of the detector at depth of 0 mm is 
considered as the surface dose. Even though the detectors may have a very shallow 


















effective point of measurement, the measured dose is not strictly the surface dose. 
This causes the discrepancy between the surface doses measured by different 
detectors [70, 36]. PPC40 chamber used in this study has an effective point of 
measurement at 1 mm below the front window and the surface dose was obtained 
by extrapolating the PDD curve [71]. For the EBT3 film, it was assumed to be at the 
surface of the film [72]. This may have resulted in the discrepancy between the two 
measurements. 
3.2.3 Surface dose comparison 
3.2.3.1 Point doses 
Point doses were measured using the measurement set-up described in section 
2.3.5.4. Measured point doses were in good agreement with point doses predicted 
by Pinnacle3 (Table 3.6). For all plans, the dose difference was within ± 3% which is 
well within the accepted clinical tolerance based on ICRU recommendations [73]. 
This verified the accuracy of treatment delivery. 
Table 3.6: Comparison between measured dose and dose predicted by Pinnacle3 
 
 
Point Dose measurement (Gy) 
Patient Plans Measured Dose (Film) Pinnacle3 Dose Difference 
Patient1_NoBolus 1.87±0.01 1.88±0.06 0.53% 
Patient1_Bolus 2.00 ±0.01 2.01±0.06 0.50% 
Patient9_NoBolus 1.96 ± 0.01 2.01±0.06 2.49% 
Patient9_Bolus 1.97±0.01 1.92±0.06 -2.60% 
 
3.2.3.2 Surface dose 
Surface doses in treatment plans were measured using the measurement set-up 
described in section 2.3.5.4. The surface dose measured with EBT3 film and the 
surface doses obtained from Pinnacle3 for both patients is given in Table 3.7. In the 
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plans without bolus, Pinnacle3 overestimated the surface dose compared to film 
measurements for Patient 1 and Patient 9 by 19.6% and 31.1% respectively. 






measured by film 
dosimetry (Gy) Surface dose calculated by Pinnacle3(Gy) 
Patient1_NonBolus 1.27±0.02 1.58±0.10 
Patient1_WithBolus 2.08±0.04 2.02±0.11 
Patient9_NonBolus 1.13±0.02 1.64±0.04 
Patient9_WithBolus 1.91±0.03 1.91±0.15 
 
Roland et al. [74] found that Pinnacle3 overestimated the average surface dose by 
15% compared to the surface doses measured with EBT films and TLD. Chung and 
colleagues measured the surface dose with Gafchromic film HS and compared it with 
surface dose calculated in Pinnacle3. They found significant discrepancies (~7.4% to 
18.5%) between the measured dose and calculated dose near surface [30]. The 
surface dose in the no bolus plan for Patient 1 (19.6%) shows good agreement with 
these results. However, for Patient 9, the discrepancy is large (31.1%). This large 
discrepancy could be due to the difficulty in matching the exact location of the film 
on the phantom during delivery and the corresponding location on the scanned 
phantom in Pinnacle3 as the setup for Patient 9 was more complex. Whilst great care 
was taken to reproduce the setup in TPS during the delivery, there could have been 
an error in placing the film on planned position.  
Pinnacle3 significantly overestimated the surface doses the new no bolus plans. The 
dose in the build-up region depends upon different factors such as the primary 
photon beam, backscattered radiation from patient, and contamination electrons 
originating in the linear accelerator head as well as in the air volume between the 
linear accelerator head and patient. Modelling the source of build-up dose is very 
complex. Hence, an electron contamination is normally added to the dose 
distribution after the photon dose is calculated in model-based calculation algorithm 
such as Collapsed Cone Convolution Superposition (CCCS). Accuracy of the dose in 
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the build-up region is greatly affected by the accuracy of the electron contamination 
model in different irradiation conditions. As stated in section 1.2.1, electron 
contamination modelling in Pinnacle3 is simplified by assuming that the electron 
contamination does not depend on the source-to-surface distance or on other beam 
modifiers. This leads to the discrepancy in the surface dose predicted by Pinnacle3 
and measured surface dose [29, 30].  
For the original plans with bolus, the discrepancy between the measured dose on 
the surface of the phantom and Pinnacle3 dose was ±3.1%, i.e. Pinnacle was able to 
accurately predict phantom surface dose under bolus. In the original plans, a bolus of 
thickness 7 mm was placed on the film. In other words, the film was at a depth of 7 
mm. Chung et al. [30] demonstrated that for shallow targets (~5 mm) the difference 
in Pinnacle3 dose and measured dose was ±5.6%. The results in this study were 





In the present study, IMRT and VMAT techniques were used for head and neck 
planning and surface doses in the original plans with bolus were compared with 
newly developed no bolus plans. In the original plan with bolus, the clinical 
objectives were to achieve optimal PTV coverage, doses to OARs within their 
tolerance limit, maximum dose in the overall plan less than 110%, and full dose to 
scar tissues. In the treatment planning study, attempts were made to generate a no 
bolus plan which would have comparable PTV coverage and dose to scar tissues as 
high as the original plan with bolus. To achieve this, two different approaches – 
‘optimizing PTV coverage’ and ‘optimizing skin dose’ - were tried. The first method 
produced no bolus plans with PTV V95% ≥ 95%. In these plans, OAR doses were 
comparable with those in the original plans and there were no hot spots outside the 
target volume. Hence, these plans achieved the first three clinical goals.  However, 
they could not achieve the required dose to scar tissues in these. On the other hand, 
in the ‘Skin dose optimization’ method, it was possible to give full doses to scar 
tissues. However, these plans produced sub-optimal dose distributions (PTV V95% < 
95% and hotspots in normal tissues) which would not be clinically acceptable.  
Surface doses predicted by Pinnacle3 were verified by film dosimetry. Surface dose 
measured with EBT3 film was validated by the surface dose measured with a parallel 
plate chamber.  Surface doses measured with the parallel plate chamber PPC40 and 
EBT3 film were 17.6% and 20.9% respectively. They were in good agreement. Surface 
dose in the original plans with bolus and the new bolus plans without bolus were 
verified by delivering plans to the cylindrical phantom. Measured surface dose in the 
original plan with bolus was in good agreement with the dose predicted by Pinnacle3. 
However, there was considerable discrepancy in measured and predicted surface 
doses for the no bolus plans. Pinnacle3 overestimated the surface doses in the no 
bolus plans.  
If the goal is to adequately treat the scar tissue whilst maintaining a good quality 
dose distribution within the target, this study demonstrates that bolus is a necessary 
component of the treatment delivery process. The scope of this study could be 
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expanded by increasing the sample size and grouping similar cases. This could help 
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Chamber signal correction factors and calibration factor for 
ionization chambers [TRS 398] 
 
kpol: Factor to correct the response of an ionization chamber for the effect of a 
change in polarity of the polarizing voltage applied to the chamber. 
 
where M+ = chamber signal obtained at positive chamber polarity, M- = chamber 
signal obtained at negative chamber polarity, M = chamber signal obtained at the 
polarity used routinely 
 
kQ,Qo : Factor to correct for the difference between the response of an ionization 
chamber in the reference beam quality Qo used for calibrating the chamber and in 
the actual user beam quality, Q.  
 
ks : Factor to correct the response of an ionization chamber for the lack of complete 
charge collection (due to ion recombination). 
 
where M1 = chamber signal reading at V1 (normal operating voltage), M2 = chamber 





kTP:  Factor to correct the response of an ionization chamber for the effect of the 
difference that may exist between the standard reference temperature and pressure 
specified by the standards laboratory and the temperature and pressure of the 
chamber in the user facility under different environmental conditions. 
 
where T and P are chamber air temperature (°C) and pressure at the time of 
measurement. T0 = 20° C and P0 = 101.3 kPa 
 
MQ : Reading of a dosimeter at the quality Q, corrected for influence quantities other 
than beam quality. Unit: C or rdg. 
 
𝐌𝐐 = 𝐌 × 𝐤𝐩𝐨𝐥 × 𝐤𝐐,𝐐𝐨 × 𝐤𝐬 × 𝐤𝐓𝐏 
 
ND, w, Qo : Calibration factor in terms of absorbed dose to water for a dosimeter at a 
reference beam quality Qo. The product MQo ND,w,Qo yields the absorbed dose to 
water, Dw,Qo, at the reference depth zref and in the absence of the chamber. Unit: 
Gy/C or Gy/rdg. 
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